IDDF2018-ABS-0088 Analysis of clinical signification KRAS and SCN5A gene expression in pancreatic cancer by TCGA datasets

Abstract

Background To investigate the prognostic significance of KRAS (Kirsten rat sarcoma viral oncogene) and SCN5A Gene mutation in pancreatic carcinoma by TCGA (the cancer genome atlas) datasets. Methods The TCGA dataset for liver cancer, gastric cancer, and pancreatic cancer in the TCGA official network, the top 100 genes affected by the number of people affected. Do Wayne map to get genes that do not coincide with the other two diseases in pancreatic cancer, and to find the genetic mutation that has a significant impact on the survival of pancreatic cancer. Results There are 13 329 mutations in pancreatic cancer, and there are 16 348 and 19 288 mutant genes in the liver and gastric cancer, respectively. The first 100 mutations were analysed from 3 data sets, and the Wayne diagram showed that there are 25 mutations in the mutant gene of pancreatic cancer, the liver cancer and gastric cancer. There are respectively 3 and 11 genes for the coincidence of pancreatic cancer with HCC and gastric cancer. It is more important that 61 gene mutations in the pancreatic cancer data set do not coincide with the other two datasets. Among them, KRAS is located on the chromosome 12 P12.1, gene type is a protein-encoding gene. The rate of mutation in pancreatic cancer is 137/163 (84.05%). The number of mutant species is 13. The total survival rate of KRAS mutations in 162 cases of pancreatic cancer was significantly lower than that no mutation in KRAS (p=1.18e-2). SCN5A is located on the chromosome 3 p22.2, gene type is a protein-encoding gene. The rate of mutation in pancreatic cancer is 10/163 (6.13%). The number of mutant species is 15. The total survival rate of SCN5A mutations in 162 cases of pancreatic cancer was significantly lower than that no mutation in SCN5A (p=2.99e-2). Conclusions There is a significant correlation between the KRAS and SCN5A gene mutations and the prognosis of pancreatic cancer.